Raffles Associates LP Increases Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Raffles Associates LP increased its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 35.8% in the second quarter, Holdings Channel.com reports. The institutional investor owned 4,357,781 shares of the company’s stock after acquiring an additional 1,147,800 shares during the period. Lineage Cell Therapeutics makes up about 4.9% of Raffles Associates LP’s holdings, making the stock its 8th largest holding. Raffles Associates LP’s holdings in Lineage Cell Therapeutics were worth $4,346,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its position in shares of Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock worth $239,000 after buying an additional 70,418 shares during the period. Comerica Bank grew its stake in shares of Lineage Cell Therapeutics by 84,745.8% in the first quarter. Comerica Bank now owns 250,295 shares of the company’s stock worth $370,000 after purchasing an additional 250,000 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Lineage Cell Therapeutics during the first quarter valued at $30,000. DCF Advisers LLC lifted its holdings in Lineage Cell Therapeutics by 14.5% in the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock worth $103,000 after purchasing an additional 12,000 shares during the period. Finally, XTX Topco Ltd bought a new position in Lineage Cell Therapeutics in the 2nd quarter valued at about $61,000. 62.47% of the stock is owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Stock Performance

LCTX opened at $0.94 on Tuesday. The firm has a market capitalization of $178.04 million, a PE ratio of -6.73 and a beta of 1.26. Lineage Cell Therapeutics, Inc. has a one year low of $0.77 and a one year high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. Lineage Cell Therapeutics had a negative return on equity of 36.30% and a negative net margin of 391.00%. The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $1.28 million. On average, research analysts forecast that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current year.

Analyst Ratings Changes

Separately, Craig Hallum assumed coverage on shares of Lineage Cell Therapeutics in a research note on Tuesday, August 20th. They issued a “buy” rating and a $4.00 price target for the company.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.